Immunome Inc 2025年季度报告

(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from_____to_____Commission File Number:001-39580 Immunome, Inc. (Exact name of registrant as specified in its charter) (425)939‑7410(Registrant’s telephone number, including area code) Not applicable.(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting companyor an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule 12b‑2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes☐No☒ There were91,710,277shares of the registrant’s common stock outstanding as of November 3, 2025. TABLE OFCONTENTS PART I – FINANCIAL INFORMATION Financial Statements (Unaudited)-Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 20243-Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and NineMonths Ended September 30, 2025 and 20244-Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Nine MonthsEnded September 30, 2025 and 20245-Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and20247-Notes to Condensed Consolidated Financial Statements9 Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations.20Item 3.Quantitative and Qualitative Disclosures about Market Risk.31Item 4.Controls and Procedures.31 PART II – OTHER INFORMATION Item 1.Legal Proceedings.32Item 1A.Risk Factors.32Item 2.Unregistered Sales of Equity Securities and Use of Proceeds.85Item 3.Defaults Upon Senior Securities.85Item 4.Mine and Safety Disclosures.85Item 5.Other Information.85Item 6.Exhibits.86 SIGNATURES PART I - FINANCIAL INFORMATION IMMUNOME, INC. Condensed Consolidated Balance Sheets(in thousands, except share and per share amounts) (unaudited) IMMUNOME, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss(in thousands, except share and per share amounts) (unaudited) IMMUNOME, INC. Condensed Consolidated Statements of Changes in Stockholders’ Equity(in thousands, except share amounts) (unaudited) IMMUNOME, INC. Condensed Consolidated Statements of Changes in Stockholders’ Equity(in thousands, except share amounts) (unaudited) IMMUNOME, INC. Condensed Consolidated Statements of Cash Flows(in thousands) (unaudited) IMMUNOME, INC. Condensed Consolidated Statements of Cash Flows(in thousands) (unaudited) IMMUNOME, INC. Notes to Condensed Consolidated Financial Statements(unaudited) 1. Nature of the business Organization Immunome, Inc., or the Company or Immunome, is a clinical-stage targeted oncology company committed to developingfirst-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. Since its inception, theCompany has devoted substantially all its resources to research and development, raising capital, building its management team,extending its intellectual property portfolio, and executing strategic partnerships and transactions. The Company is subject to risksand uncertainties common to companies in the biotechnology industry at Immunome's stage including, but not limited to, risksassociatedwith research,development,and manufacturing activities,uncertain results of preclinical and clinical testing,development of new technological innovations and products by competitors, dependence on key personnel, partners and third-partyvendors, protection of proprietary